Piramal - Linezolid Injection

Treatment of infecons caused by suscepble strains of the designated microorganisms in the specific condions listed in the FPI.

See FPI for full details. Linezolid injecon should be administered by intravenous infusion over a period of 30 to 120 minutes. For nosocomial pneumonia, community-acquired pneumonia and complicated skin, skin structure infecons and vancomycin-resistant Enterococcus faecium infecons, including concurrent bacteremia, the recommended pediatric paents (birth through 11 years of age) dosage of Linezolid injecon is 10 mg/kg intravenously every 8 hours for 10-14 days. For adults and adolescents (12 years and older), the recommended daily dose is 600 mg intravenously every 12 hours for the recommended duraon of treatment (14-28 days). Maximum duraon of treatment should be 28 days.

Linezolid injecon is contraindicated in paents who have known hypersensivity to Linezolid or any of the other product components. Linezolid should not be used in paents taking any medicinal product which inhibits monoamine oxidases A or B (e.g., phenelzine, isocarboxazid) or within two weeks of taking any such medicinal product.

Most common side effects (>5% of adult and/or pediatric paents) treated with Linezolid injecon include: diarrhea, voming, headache, nausea, and anemia.